Literature DB >> 3415951

Retinoblastoma in Great Britain 1969-80: incidence, treatment, and survival.

B M Sanders1, G J Draper, J E Kingston.   

Abstract

Patients with retinoblastoma diagnosed from 1969 to 1980 have been followed up for periods of up to 17 years. Data from a previous study of patients diagnosed from 1962 to 1968 have been included for analysis of incidence and second primary tumours, and for study of trends in treatment. The registration rate in Britain (which may be about 10% less than the true incidence) is about one in 23,000 live births, approximately 40% of cases being known to be genetic. There is no apparent trend in incidence during the period covered by these two studies. The three-year survival rate in 88%. Patients with bilateral tumours have a better survival rate than those with unilateral tumours for the first few years, but their long-term survival rate is worse because of later deaths from ectopic intracranial retinoblastoma or second primary neoplasms. Older children tend to have a worse prognosis, which is related to the fact that their tumours are diagnosed at a more advanced stage. There is a significantly higher survival rate for boys than for girls; this is partly accounted for by difference in age and stage at diagnosis between the sexes. Children referred to units specialising in the treatment of retinoblastoma have a higher three-year survival rate than those treated at other hospitals. Comparing methods of treatment between the periods 1962-8 and 1969-80, we find there has been a trend towards more conservative treatment. The use of chemotherapy is now usually reserved for recurrences and metastases and for palliative treatment in terminal retinoblastoma.

Entities:  

Mesh:

Year:  1988        PMID: 3415951      PMCID: PMC1041531          DOI: 10.1136/bjo.72.8.576

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  The evaluation and current concept of retinoblastoma therapy.

Authors:  A B REESE; R M ELLSWORTH
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1963 Mar-Apr

2.  Chromosome 13 homozygosity in osteosarcoma without retinoblastoma.

Authors:  T P Dryja; J M Rapaport; J Epstein; A M Goorin; R Weichselbaum; A Koufos; W K Cavenee
Journal:  Am J Hum Genet       Date:  1986-01       Impact factor: 11.025

3.  Retinoblastoma: a prototypic hereditary neoplasm.

Authors:  A G Knudson
Journal:  Semin Oncol       Date:  1978-03       Impact factor: 4.929

4.  Ectopic intracranial retinoblastoma in childhood.

Authors:  J E Kingston; P N Plowman; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1985-10       Impact factor: 4.638

Review 5.  Retinoblastoma: clues to human oncogenesis.

Authors:  A L Murphree; W F Benedict
Journal:  Science       Date:  1984-03-09       Impact factor: 47.728

6.  Orbital recurrence of retinoblastoma.

Authors:  J Hungerford; J Kingston; N Plowman
Journal:  Ophthalmic Paediatr Genet       Date:  1987-03

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

Review 8.  Genetics of retinoblastoma.

Authors:  F Vogel
Journal:  Hum Genet       Date:  1979-11-01       Impact factor: 4.132

9.  Incidence of retinoblastoma in the United States.

Authors:  T W Pendergrass; S Davis
Journal:  Arch Ophthalmol       Date:  1980-07

10.  Second primary neoplasms in patients with retinoblastoma.

Authors:  G J Draper; B M Sanders; J E Kingston
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

View more
  33 in total

1.  Treatment protocols, specialist centers, and end results.

Authors:  C A Stiller
Journal:  BMJ       Date:  1990-01-06

2.  Association Between Genotype and Phenotype in Consecutive Unrelated Individuals With Retinoblastoma.

Authors:  Flore Salviat; Marion Gauthier-Villars; Matthieu Carton; Nathalie Cassoux; Livia Lumbroso-Le Rouic; Catherine Dehainault; Christine Levy; Lisa Golmard; Isabelle Aerts; François Doz; Fidéline Bonnet-Serrano; Stéphanie Hayek; Alexia Savignoni; Dominique Stoppa-Lyonnet; Claude Houdayer
Journal:  JAMA Ophthalmol       Date:  2020-08-01       Impact factor: 7.389

3.  Retinoblastoma--trends in conservative management.

Authors:  J Dudgeon
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

4.  Survival of patients with cancer.

Authors:  C A Stiller
Journal:  BMJ       Date:  1989-10-28

5.  Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995.

Authors:  A C Moll; D J Kuik; L M Bouter; W Den Otter; P D Bezemer; J W Koten; S M Imhof; B P Kuyt; K E Tan
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

6.  Mutation risk associated with paternal and maternal age in a cohort of retinoblastoma survivors.

Authors:  Melissa B Mills; Louanne Hudgins; Raymond R Balise; David H Abramson; Ruth A Kleinerman
Journal:  Hum Genet       Date:  2011-12-28       Impact factor: 4.132

7.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

Authors:  S E Coupland; N Bechrakis; A Schüler; I Anagnostopoulos; M Hummel; N Bornfeld; H Stein
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

8.  A multicentre report from the Mexican Retinoblastoma Group.

Authors:  C Leal-Leal; M Flores-Rojo; A Medina-Sansón; F Cerecedo-Díaz; S Sánchez-Félix; O González-Ramella; F Pérez-Pérez; R Gómez-Martínez; A Quero-Hernández; E Altamirano-Alvarez; F Alejo-González; J Figueroa-Carbajal; A Ellis-Irigoyen; I Tejocote-Romero; R Cervantes-Paz; F Pantoja-Guillén; L Vega-Vega; F Carrete-Ramírez
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

9.  The genetics of retinoblastoma, revisited.

Authors:  A Naumova; C Sapienza
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

10.  External beam radiotherapy for retinoblastoma: I. Whole eye technique.

Authors:  J L Hungerford; N M Toma; P N Plowman; J E Kingston
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.